MX9708537A - Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4. - Google Patents

Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4.

Info

Publication number
MX9708537A
MX9708537A MX9708537A MX9708537A MX9708537A MX 9708537 A MX9708537 A MX 9708537A MX 9708537 A MX9708537 A MX 9708537A MX 9708537 A MX9708537 A MX 9708537A MX 9708537 A MX9708537 A MX 9708537A
Authority
MX
Mexico
Prior art keywords
disclosed
polypeptides
beta
chemokine beta
chemokine
Prior art date
Application number
MX9708537A
Other languages
Spanish (es)
Inventor
Craig A Rosen
Steven M Ruben
Haodong Li
Mark D Adams
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of MX9708537A publication Critical patent/MX9708537A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Human Ck'beta'-8, MIP-4 and Ck'beta'-1 and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and for detecting altered concentrations of the polypeptides.
MX9708537A 1995-05-05 1995-06-23 Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4. MX9708537A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44688195A 1995-05-05 1995-05-05
PCT/US1995/009058 WO1996034891A1 (en) 1995-05-05 1995-06-23 Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4

Publications (1)

Publication Number Publication Date
MX9708537A true MX9708537A (en) 1998-02-28

Family

ID=23774170

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708537A MX9708537A (en) 1995-05-05 1995-06-23 Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4.

Country Status (8)

Country Link
EP (1) EP0871672A4 (en)
JP (2) JPH11505417A (en)
KR (1) KR19990008335A (en)
CN (2) CN1515672A (en)
AU (1) AU3134695A (en)
CA (1) CA2220123A1 (en)
MX (1) MX9708537A (en)
WO (1) WO1996034891A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6623942B2 (en) 1994-03-08 2003-09-23 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polynucleotides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
EP0859842A4 (en) * 1995-09-29 1999-02-24 Smithkline Beecham Corp SHORT FORMS OF CHEMOKINE -g(b)-8
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
ES2256885T3 (en) 1996-04-30 2006-07-16 Pharis Biotec Gmbh NEW TYPE CHEMIOCINES CC.
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
CN1239510A (en) * 1996-09-30 1999-12-22 人类基因组科学公司 Compsns. and methods for treating disease states with myeloid progenitor inhibitory factor-1(MPIF-1), monocyte colony inhibitory factor (M-CIF) and macrophage inhibitory factor-4(MIP-4)
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
DK1015477T3 (en) 1997-05-30 2011-02-07 Human Genome Sciences Inc 32 human secreted proteins
ES2303358T3 (en) 1997-11-03 2008-08-01 Human Genome Sciences, Inc. VEGI, AN INHIBITOR OF ANGIOGENESIS AND TUMOR GROWTH.
KR19990042713A (en) * 1997-11-27 1999-06-15 허일섭 Method for preparing CDNA and recombinant LKN-1 of C 6 beta-chemokine LKN-1 isolated from human
JP2002506625A (en) 1998-03-19 2002-03-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Cytokine receptor common γ chain-like
CA2332573A1 (en) * 1998-07-06 2000-01-13 Elizabeth Esther Mary Bates Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12), md-1, md2 and cyclin e2, related reagents and methods
EP0974357A1 (en) 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
US6495128B1 (en) 1998-11-10 2002-12-17 Human Genome Sciences, Inc. Human chemokine β-7 deletion and substitution proteins
CA2387545A1 (en) * 1999-10-14 2001-04-19 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
WO2001031016A2 (en) * 1999-10-25 2001-05-03 Euroscreen S.A. Processed human chemokines phc-1 and phc-2
EP1167527A1 (en) * 2000-06-22 2002-01-02 Euroscreen S.A. Processed human chemokines PHC-1 and PHC-2
EP2067488A1 (en) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albumin fusion proteins
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP1176200A3 (en) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances
AU2001271621A1 (en) 2000-06-28 2002-01-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
ATE497007T1 (en) 2000-08-25 2011-02-15 Basf Plant Science Gmbh POLYNUCLEOTIDES CODING FOR PRENYL PROTEASES FROM PLANT
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
ES2327126T3 (en) 2003-12-05 2009-10-26 Oxagen Limited AGENTS THAT MODULATE THE ACTIVITY OF CCRL2 AND METHODS OF USING THE SAME.
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2054437A2 (en) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
US9499605B2 (en) 2011-03-03 2016-11-22 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290455A4 (en) * 1986-01-08 1989-01-18 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the same.
EP0548214B1 (en) * 1990-09-14 1999-03-10 Chiron Corporation EXPRESSION OF MACROPHAGE INDUCIBLE PROTEINS (MIPs) IN YEAST CELLS
DK0735818T3 (en) * 1993-12-22 2004-07-26 Human Genome Sciences Inc Macrophage-inflammatory proteins MIP-3, Mip-4 and Mip-1gamma
US20030105293A1 (en) * 1993-12-24 2003-06-05 Wolf-Georg Forssmann Human circulating cytokine cc-1
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
US5874211A (en) * 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils

Also Published As

Publication number Publication date
JPH11505417A (en) 1999-05-21
CA2220123A1 (en) 1996-11-07
AU3134695A (en) 1996-11-21
WO1996034891A1 (en) 1996-11-07
KR19990008335A (en) 1999-01-25
JP2003102486A (en) 2003-04-08
EP0871672A1 (en) 1998-10-21
CN1125082C (en) 2003-10-22
CN1515672A (en) 2004-07-28
CN1186501A (en) 1998-07-01
EP0871672A4 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
MX9708537A (en) Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4.
DE69433648D1 (en) HUMAN CHEMOKIN POLYPEPTIDES
DE69533627D1 (en) Humanes chemokin beta-13
MX9701330A (en) Human chemokine beta-9
WO1997035010A8 (en) Chemokine alpha 2
EP0814158A3 (en) Human C3a receptor variant; uses in diagnostics and therapeutics
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
EP0792370A4 (en) INTERLEUKIN-1 -g(b) CONVERTING ENZYME LIKE APOPTOSIS PROTEASE-3 AND 4
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
DE69841140D1 (en) INTERLEUKIN-17 RECEPTOR-SIMILAR PROTEIN
GR3024263T3 (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
ATE366316T1 (en) MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC TO HUMAN TUMOR NECROSIS FACTOR
AU2881389A (en) Human ifn-beta 2/il-6, its purification and use
DE69230136T2 (en) CYTOKIN-INDUCED PROTEIN, TSG-6, HIS DNA AND USE
EP0812913A3 (en) HR-1 receptor, a receptor of the cytokine receptors family
NO964465D0 (en) Heparin-binding protein for the treatment of sepsis, and methods for its preparation
MX9709090A (en) Human chemokine beta-11 and human chemokine alpha-1
FR2653445B1 (en) DNA FRAGMENT ENCODING THE INTERFERON ALPHA RECEPTOR GENE AND PROCESS FOR THE PREPARATION OF A CORRESPONDING PROTEIN.